US OptionsDetailed Quotes
AMGN241213C297500
- 0.21
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
0.21Open0.21Pre Close0 Volume88 Open Interest297.50Strike Price0.00Turnover2333.63%IV10.01%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.21Extrinsic Value100Contract SizeAmericanOptions Type0.0375Delta0.0057Gamma1288.67Leverage Ratio-294.5637Theta0.0000Rho48.36Eff Leverage0.0005Vega
Amgen Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
9
1
4
Columns These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over.
It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed.
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
3
$Amgen (AMGN.US)$ plsssss buck up!!! 🚀
1
Today, $Amgen (AMGN.US)$ announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again).
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
+1
3
The market again hit records Tuesday, reacting mostly positively toward incoming President-Elect Trump's comments overnight that he would put a 25% tariff on our neighbors in Canada and Mexico and 35% on Chinese goods, our three largest trading partners.
According to Census Bureau data, there are price hikes in the goods on 41% of the U.S.'s total imports; there has been $1.6T trade so far in 2024. A blanket ...
According to Census Bureau data, there are price hikes in the goods on 41% of the U.S.'s total imports; there has been $1.6T trade so far in 2024. A blanket ...
35
9
12
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Amgen (AMGN.US)$ A 20% weight loss reduction in one year is fantastic and healthy from a medical standpoint. A 5 foot 4 inches woman at 180 pounds would loss guaranteed 36 pounds over 1 year be down to a much healthier 144 pounds. This is impressive results. I don’t understand the selloff. The human body should lose weight in a healthy fashion. I don’t know what you guys are expecting . This is great news .
5
1
$Amgen (AMGN.US)$ feels overdone for decent Phase 2 data.
1
Good morning, traders. Happy Tuesday, November 26th. The Dow closed at a high yesterday, and the S&P 500 hit a trading record.
You will not make it through today without the news and animal spirits moving markets. My name is Kevin Travers, here is what's live:
$Amgen (AMGN.US)$ investors tightened their belts and shaved 11% of the stock price Tuesday after the firm said in a press release their Phase 2 study of MariTide showed ...
You will not make it through today without the news and animal spirits moving markets. My name is Kevin Travers, here is what's live:
$Amgen (AMGN.US)$ investors tightened their belts and shaved 11% of the stock price Tuesday after the firm said in a press release their Phase 2 study of MariTide showed ...
37
23
5
$Amgen (AMGN.US)$ whats going on???
2
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.